The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
A new study carried out by academics at the University of Bristol's Animal Welfare and Behaviour research group has revealed that chickens empathise. So, if you've wondered why the chicken crossed the road, it was probably to help a friend.
More specifically, the research - funded by the BBSRC Animal Welfare Initiative and published online in the Proceedings of the Royal Society B. - demonstrated that domestic hens show a clear physiological and behavioural response when their chicks are mildly distressed.
Researchers say the study is the first to demonstrate that birds possess one of the important attributes that underpins empathy, and the first study to use both behavioural and physiological methods to measure these traits in birds.
During one of the controlled procedures, when the chicks were exposed to a puff of air, the hens' heart rate increased and eye temperature decreased. The hens also changed their behaviour, and reacted with increased alertness, decreased preening and increased vocalisations directed to their chicks.
Some of these responses have previously been used as indicators of an emotional response in animals. In domestic chickens, time spent standing alert is associated with higher levels of fear. Previous research carried out by the same group has shown that hens also selectively avoid surroundings associated with high levels of standing and low levels of preening.
Jo Edgar, PhD student in the School of Veterinary Sciences, said: "The extent to which animals are affected by the distress of others is of high relevance to the welfare of farm and laboratory animals.
"Our research has addressed the fundamental question of whether birds have the capacity to show empathic responses.
"We found that adult female birds possess at least one of the essential underpinning attributes of 'empathy'; the ability to be affected by, and share, the emotional state of another."
The researchers say they used chickens as a model species because, under commercial conditions, chickens will regularly encounter other chickens showing signs of pain or distress due to routine husbandry practices or because of the high levels of conditions such as bone fractures or leg disorders.
Reference:'Avian maternal response to chick distress', J L Edgar, J C Lowe, E S Paul, C J Nicol, published online ahead of print Proceedings of the Royal Society B, 9 March 2011.
Picture:Gemma Richards, University of Bristol
Consequently, the company says the sheep sector is going to have to take a more proactive approach to parasite control if it is to achieve the best possible environmental standards.
The research by SRUC and the Moredun Research Institute showed parasite infections in lambs can lead to a 33% increase in methane output1 and that parasitism is one of the top three livestock diseases which increase greenhouse gas (GHG) emissions2 and is cost-effective to manage.
Eurion Thomas, European operations manager at Techion, says that despite current emissions from sheep being over-exaggerated, the sector will need to act if the NFU’s aspiration for net zero emissions from agriculture by 2040, is to be achieved.
Eurion said: "While targets to further reduce GHG emissions may appear to be burdensome, there are some simple steps farmers can take that’ll help minimise emissions while also improving business profitability. This includes incorporating regular faecal egg counts (FEC) into routine flock management to increase the accuracy of worm control.
"Worms reduce performance, in particular feed conversion ratio (FCR) meaning animals take longer to finish at lower weights. In addition, the research shows animals with worms release more methane per day due to the upset they cause to the digestive system.
"Better parasite control can therefore reduce number of days to finishing, improving production efficiency and lowering methane emissions per unit of meat produced. The number of days to slaughter and FCR are also correlated to profit margins, providing an opportunity to improve the bottom line."
Eurion says one of the reasons endemic diseases such as worm burdens are so detrimental to production efficiency and emissions is because often the disease has significantly impacted animal performance before it has been identified. Regular faecal egg counts (FEC) and an accurate treatment programme are therefore crucial.
Eurion said: "FECPAKG2 is the latest in image-based, internet-connected, FEC technology and means testing can be carried out virtually anywhere by anyone, including on-farm by the farmer.
"Because digital images of parasite eggs are produced, analysed and stored online, FECPAKG2 provides rapid results while offering greater quality control and auditability. This is encouraging more frequent testing and better decision making at farm level."
A collaborative research project between Sainsbury’s and Techion3 showed accurate treatment of the right animals, with the right wormer, at the right time, improved daily liveweight gains (DLWG) while reducing wormer use in sheep by up to 50%.
Eurion said: "Addressing the environmental impact of red meat production is arguably one of the biggest challenges the sector faces and introducing FEC is one simple way farmers can proactively work towards this, while improving business profitability."
References
The announcement came hot on the heels of announcements from Ceva and Boehringer that they too had vaccines in the pipeline.
Syvazul BTV3 is licensed to reduce viraemia, prevent mortality and reduce clinical signs and lesions in sheep and for the active immunisation against bluetongue virus serotype 3 in cattle.
Like all vaccines currently available for this serotype, the vaccine will not prevent infection and vaccinated animals will still be subject to bluetongue movement controls and trade restrictions currently in place.
Administered as a single 2ml dose subcutaneously in sheep and as two 4ml intramuscular doses 3 weeks apart in cattle, Syvazul BTV3 contains inactivated Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023.
The vaccine is licenced for use during pregnancy and lactation in both sheep and cattle.
The onset of immunity is 28 days after the primary vaccine in sheep. A single booster revaccination dose of 2ml for sheep and 4ml for cattle is recommended after 12 months.
Presented in two pack sizes, 80ml and 200ml, Syvazul BTV3 vaccine has a shelf life of 2 years from manufacture and a broach life of 10 hours.
Licensing for use will be geographic, based upon high risk counties or by specific licence from the APHA.
The BVA has expressed its concern that almost two-thirds of food companies have no information on their commitment to stunning animals before slaughter – with only 4% having a "universal commitment".
The findings were published in the Business Benchmark on Farm Animal Welfare report (BBFAW, published 27 January) and also show that slaughter without pre-stunning is the only welfare measure showing a decline in the percentage of food companies that have a specific policy on the practice, down from 34% in 2014 to 32% in 2015.
BVA has run a long-standing and high profile campaign to end non-stun slaughter in the UK, with a public petition in 2015 gaining 120,000 signatures. BVA, together with all leading farm animal welfare organisations, believes that all animals should be stunned before slaughter to render them insensible to pain. Scientific evidence supports the use of pre-stunning to safeguard animal welfare. In 2015, two-thirds of BVA members listed the issue as one of their top priorities for government.
BVA President Sean Wensley said: "Vets and the public are united in their concern about animal welfare at slaughter. There are several positive findings on the growing commitment of food companies towards farm animal welfare in the BBFAW report, which we welcome, but the report highlights a disappointing lack of commitment towards animal welfare at the time of slaughter. The European Commission’s study of 13,500 meat consumers across Europe found that 72% wanted information about the stunning of animals at slaughter. Food companies need to sit up and take consumers’ concerns about humane slaughter seriously. People want to be assured that farmed animals receive both a good life and a humane death."
The Royal College of Veterinary Surgeons (RCVS) has clarified the legal position regarding the disbudding of goats, following recent media reports concerning undercover filming on UK goat farms.
The carrying out of any activity which amounts to veterinary surgery is restricted to veterinary surgeons unless there is a suitable exemption that allows other people to do it. The removal of the horn-bud of goats (disbudding) is considered veterinary surgery under the provisions of the Veterinary Surgeons Act 1966 (the Act).
Schedule 3 of the Act provides certain exemptions to the restriction on carrying out veterinary surgery, such as those allowing veterinary nurses and student veterinary nurses to undertake any medical treatment or any minor surgery (not involving entry into a body cavity) in certain circumstances. However, Schedule 3 specifically provides that these exemptions do not allow non-veterinary surgeons to undertake the disbudding of goats, except the trimming of the insensitive tip of an in-growing horn which, if left untreated, could cause pain or distress.
There are no other Exemption Orders covering the disbudding of goats and therefore this procedure may only be undertaken by veterinary surgeons.
The Mutilations (Permitted Procedures) (England) Regulations 2007, the Mutilations (Permitted Procedures) (Wales) Regulations 2007 and the Prohibited Procedures on Protected Animals (Exemptions) (Scotland) Regulations 2007 all include disbudding of goats as a procedure which can be carried out for non-therapeutic reasons. However, this secondary legislation is subject to the restrictions in the Veterinary Surgeons Act 1966 and therefore disbudding of goats is restricted to veterinary surgeons.The Welfare of Animals (Permitted Procedures By Lay Persons) Regulations (Northern Ireland) 2012 currently include disbudding of goats as a procedure which may be carried out by non-veterinary surgeons. However, the Veterinary Surgeons Act 1966 applies to Northern Ireland and the Regulations are scheduled to be amended later in 2012. This will make it clear that only veterinary surgeons may disbud goats in the UK.
The secondary legislation in the UK does not explicitly require anaesthetic to be administered when disbudding goats. However, disbudding should be carried out by veterinary surgeons in accordance with good practice and in such a way as to minimise pain and suffering caused to the animal, which should include use of an anaesthetic.
In summary, only a veterinary surgeon may undertake the disbudding of goats and due to the nature of the procedure, veterinary surgeons disbudding goats should administer anaesthetic.
The decision comes after 13 dead wild birds were confirmed to have the virus in Warwickshire.
Last week 17 wild birds were tested positive in Dorset and 31 infected birds have now been identified at the Dorset site. At that time Defra responded by putting a local prevention zone in place and, now it is known the disease is not isolated to the Dorset site, the prevention zone has been extended across the country as a precautionary measure.
The prevention zone means bird keepers across the country must:
Those keepers who have more than 500 birds will need to take extra biosecurity measures that include restricting access to non-essential people, changing clothing and footwear before entering bird enclosures and cleaning and disinfecting vehicles.
The birds in Warwickshire are still being tested but it is expected that it will be the same H5N6 strain of bird flu that was found in the wild birds in Dorset and has been circulating wild birds across Europe. Public Health England have advised the risk to public health is very low with the Food Standards Agency also offering reassurance that bird flu does not pose a food safety risk for UK consumers. Defra has confirmed that the H5N6 strain is different to the strains which affected people in China last year.
Although it does not represent a threat to public, it is highly infectious and deadly to birds.
British Veterinary Association (BVA) President John Fishwick said: "I’d encourage vets to reassure their clients that this strain of Avian Influenza poses a very low risk to public health and the food chain. However, there is clearly a need to try to contain further spread of the disease, which has almost certainly come from migratory birds, and vets and poultry owners should follow the new prevention zone measures and remain vigilant for signs of bird flu."
British Veterinary Poultry Association (BVPA) President Phil Hammond added: "It’s really important that all bird keepers heed biosecurity advice issued by Defra, and maintain the highest biosecurity standards. Any suspicion of Avian Influenza should be reported to the APHA as soon as possible."
Up-to-date advice and guidance on Avian Influenza is available on the Gov.UK website, including how to spot it, what to do if you suspect it, and measures to prevent it:
https://www.gov.uk/guidance/avian-influenza-bird-flu#about-avian-influenza
For further advice on Avian Influenza contact the Defra Helpline on 03459 33 55 77.
Photo: Wild Birds, Shutterstock / aDam Wildlife
The aim of the survey, which closes on 16th June, is to recognise and help raise awareness of the multiple challenges faced by veterinary surgeons undertaking roles for Government as a distinct subset of the veterinary profession.
The Association of Government Veterinarians says that following the survey, it'll be producing a report which identifies issues which affect government vets' wellbeing, identifies existing tools to promote wellbeing within Government and considers developing new ones if necessary. It will also consider best practice and any gaps in the wellbeing services currently available that vets in Government roles would benefit from.
To take part in the survey, visit: https://www.surveymonkey.co.uk/r/vetswellbeing
You can read more about the survey here: https://vets.blog.gov.uk/2018/04/06/how-are-you-feeling-association-of-government-vets-wellbeing-survey-launched/
Photo: Christine Middlemiss introduces the survey.
BSAVA Summit will take place from 16-17 December 2019 at the Royal College of Physicians in London and will involve a series of high-profile keynote speakers and interactive workshops.
The Association says the event will deliver CPD differently to other veterinary meetings, with most sessions run as facilitated workshops to enable delegates to lead and shape discussions.
Confirmed facilitators include RCVS CEO Lizzie Lockett, BEVA President Renate Weller, Director of Clinical Research and Excellence in Practice at VetPartners Rachel Dean and Small Animal Medicine Specialist and Advanced Practitioner in Veterinary Cardiology Dr Kit Sturgess. Each day delegates can choose three out of a total of five workshops. Online forums will be used in the run up to BSAVA Summit to develop ideas and thinking for the workshops before the event.
Day one will focus on ‘The Profession Today’ and topics will include workforce issues, telemedicine, specialism, the future of advanced practitioners and regulation of the profession.
Day two will explore the future of ‘The Profession Tomorrow’ with topics including communication, over-diagnosis, over-treatment and innovation.
On the Monday evening delegates, speakers and facilitators will be able to network at a drinks reception in the library at the Royal College of Physicians.
BSAVA President Sue Paterson said: "We have launched BSAVA Summit to address the rising demand for a space to debate important topics, challenge mindsets and question accepted benchmarks. Following feedback from our members and the profession, Summit will revolutionise veterinary conference norms with a free-flow approach to champion active debate, discussion and reflection.
"There is a growing need to tackle some of the ethical and professional problems that face vets today such as over diagnosis, the role of specialists in practice, and research in practice. Importantly, the format of the discussion forums means that whilst the debate is led by a facilitator, the delegates will drive the agenda to arrive at stimulating and satisfying outcomes. It has been designed to fit with the new outcomes-based approach proposed by the RCVS where veterinary professionals are encouraged to plan their CPD, do their CPD and reflect on what they have learnt.
"The delegates are the key to the event, and Summit should attract people who want to be involved, want to input, want to make a difference and want to help drive the profession forward. I already have people eagerly emailing me wanting news of when the registration goes live.
"Summit aims to help delegates take a hard look at the way they work. Our aim is for each delegate to set themselves personal goals and we will be following up in 3 months to see if they have achieved them."
The BSAVA says that although the Summit is primarily targeted at experienced small animal practitioners, all vets, including equine and large animal practitioners, are welcome to attend.
The full programme will be available and registration will open online on 17th June. BSAVA members will have an opportunity to book advance tickets, with general sale opening two weeks later.
For further information visit www.bsavasummit.com.
The new code is one of a series of welfare codes currently being reviewed and updated by the Department for Environment, Food and Rural Affairs (Defra) following recent consultations.
BVA President John Fishwick said: "We warmly welcome these updates and we are particularly pleased to see the vital role the veterinary profession plays in maintaining poultry welfare recognised throughout the new code.
"We are also delighted to see the benefits of veterinary surveillance systems highlighted, with owners and keepers encouraged to use local and national disease surveillance sources to better understand poultry disease patterns and their local health and welfare landscape. This was a key element in our joint consultation response and reflects BVA’s recently published Position on veterinary scanning surveillance (animal health and disease monitoring).
"We are also pleased to see signposting within the Code of Practice to the Humane Slaughter Association’s Code of Practice for the Disposal of Chicks in Hatcheries, which outlines in detail information about humane methods of killing and good practice.
"The British poultry industry has some of the highest welfare standards in the world and the veterinary profession is fully committed to working with Defra on further enhancing animal welfare codes to reflect best industry practice."
Photo: Flock of Chickens (Gallus gallus domesticus) Roaming Freely in Front of Chicken Sheds on a Farm in the Rural Village of Chenson, Devon. Shutterstock / Peter Turner Photography
Intervet/Schering-Plough Animal Health has announced the launch of Nuflor Minidose - a 50% more concentrated, but less viscous solution of its proven Nuflor antibiotic.
Nuflor Minidose is licensed for the treatment and prevention of bacterial BRD. Intervet/Schering-Plough Animal Health livestock veterinary adviser Rosemary Booth MRCVS said: "It delivers all the rapid efficacy entrusted in Nuflor, but at a lower volume. Whereas a 20ml dose of Nuflor will treat a 150kg animal, the same volume of Nuflor Minidose will cover a 225kg beast. Compared with Nuflor, the new Minidose formulation is easier to administer delivering a less viscous florfenicol solution, with a 62% improvement in viscosity at 15°C and 59% at 5°C."
Rosemary added that Nuflor Minidose is effective against the main bacterial causes of pneumonia: P. multocida, M. haemolytica and H. somni. "Florfenicol is the only antibiotic offering 100% sensitivity to these three key BRD causes in recent trials and its kill effect also ensures that within 24 hours bacteria levels are low enough to prevent any re-growth."
She also pointed out that the new, more concentrated florfenicol solution presents vets with an improved batch treatment option for controlling BRD considering Nuflor is recognised as an effective metaphylactic
"Batch treatment prevents BRD from spreading. Trials with Nuflor have demonstrated the benefit of metaphylactic batch treatment of sick calves in a pen once at least 20% of the animals exhibit disease symptoms. Nuflor was significantly more efficacious than a control in preventing the spread of BRD in healthy calves exposed to infected animals," she explains.
"The bacteria responsible for BRD are found in the respiratory tract of healthy cattle and stress or a greater pathogen load - such as exposure to sick calves - can easily trigger disease. BRD bacterial numbers can double every 30 minutes and in 24 hours, one bacterium can multiply to billions. Batch treatment kills the bacteria before they multiply, release toxins and cause permanent lung damage."
New Nuflor Minidose is licensed for injection subcutaneously for the prevention of BRD at a dose rate of 4ml/45kg and has a 64-day meat withdrawal period.
Speaking at the MSD Animal Health sponsored National Mastitis Panel, David said that more widespread understanding of the issues is urgently required particularly amongst farmers and cattle vets if real progress is to be made.
David said: "There are some notable examples of veterinary practices that have worked with their clients to eliminate the use of CIAs. These are the exceptions, but they illustrate what is possible. As an industry, we need to speed up the rate of change and make a concerted effort to ensure more responsible use of antibiotics becomes the norm, sooner rather than later."
David quoted the British Cattle Veterinary Association (BCVA) position on the responsible use of medicines, which includes the recommendation of minimal use of third and fourth generation cephalosporins, fluoroquinalones and colistin, with these CIAs being limited to use where it has been demonstrated by sensitivity testing that they are the only suitable option to avoid unnecessary suffering.
"There has been agreement on this position amongst the veterinary associations, farmer organisations and milk buyers, but there needs to be more widespread awareness at producer level, particularly within the vet and farmer relationship.
"Farms with a robust herd health plan, where challenges are reduced, will be in the best position to minimise use of CIAs. This takes time and is most effective where there is good cooperation between the farm and its veterinary practice.
"Achieving a significant reduction in the use of CIAs voluntarily will not only minimise the likelihood of disruptive and potentially punitive legislation but will put our cattle industry on the front foot and strengthen its position in global markets."
An impurity was detected during stability monitoring. The impurity was isolated and the best estimate of identity indicated that the impurity is carprofen related.
The problem affects a limited number of batches and is identifiable through quality control testing. The concentration of the process impurity does not increase over time.
This recall is for the following batches only:
Norbrook is contacting wholesale dealers and veterinary surgeons to examine inventory and quarantine products subject to this recall.
For further information regarding the recall, contact Gary Mckee on 0044 2830 264435 or by email: gary.mckee@norbrook.co.uk
Norbrook Laboratories has announced the addition of new indications to its Loxicom (meloxicam) products, two regarding its use in cats, and the other in calves.
Loxicom 5mg/ml solution for injection for dogs and cats is now indicated for the management of post-operative pain in cats. An injection given around the time of surgery can be followed up with a course of Loxicom 0.5 mg/ml oral suspension for cats. Alternatively, for cats where no follow-up oral treatment is possible, for example with feral cats, a larger dose of the injectable formulation can be given at the time of surgery.
Norbrook's EU Veterinary Advisor, Rebekah Dudek MRCVS, said: "Norbrook is pleased to be able to now offer vets two on-licence choices in relation to how they want to use their 5mg/ml meloxicam injection in cats. This gives vets the flexibility they need to be able to deal effectively with the wide variety of cases they see every day."
Loxicom 20mg/ml solution for injection for cattle, pigs and horses has now been licenced for the relief of post-operative pain following dehorning in calves.
Norbrook says that the use of a non-steroidal antiinflammatory drug (NSAID) alongside local anaesthetic has clear benefits for animal welfare, and that use at this time is also shown to offer economic benefits to the farmer, with increased food-conversion efficiency compared to untreated calves1.
Rebekah said: "Dehorning in calves has long been known as a painful procedure, with a negative impact on feed intake in the post-operative period. With our latest licence, Loxicom 20mg/ml can now be used for relief of this potentially economically important post-operative pain in calves."
Reference
BCF, Instrumentation Concept and VetSonic have collected 'VetSurgeon.org Best Stand Awards'; the first two at BEVA Congress and the latter at BCVA Congress.
Judging for the BEVA Congress awards was undertaken by members of BEVA Council. BCF picked up the Best Large Stand Award which was presented by outgoing President, Andrew Harrison.
Pictured left to right: BEVA President, Andrew Harrison, Gavin Mitchell and Carole Irvine of BCF, and John Alborough representing VetSurgeon.org.
Instrumentation Concept picked up the Best Shell Scheme Award
Pictured left to right: Outgoing BEVA President, Andrew Harrison; Tahir Afzac of Instrumentation Concept; John Alborough representing VetSurgeon.org, and Sheraz Ishaque of Instrumentation Concepts
At BCVA Congress, Vetsonic won the Best Stand Award.
Pictured left to right: Clare Walsh, Vetsonic Director; John Alborough, All Round Good Egg representing VetSurgeon.org; Gareth Hateley, then President BCVA and Sarah Vermont, Marketing Manager Vetsonic.
MSD has announced that the broad-spectrum clostridial disease vaccine for sheep and cattle, Bravoxin 10, is now available in a new 6 x 100ml farm vaccination pack. The pack contains enough vaccine for 600 sheep or 300 cattle boosters.
Buyers of the new farm pack will also get a free vaccine applicator worth £20. The new Bravoxin 10 applicator benefits from the sterimatic system, which protects and sterilises the vaccination needle with each injection. MSD says it can also be placed down between doses without risk of needle damage, self-injection or needing to remove the vaccine bottle.
Bravoxin 10 protects both cattle and sheep from clostridial diseases like blackleg and black disease, as well as other conditions caused by clostridial bacteria that usually kill the animal once infection has become established. The vaccine protects against disease caused by the 10 main clostridial bacteria; C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.
Bayer Animal Health has launched Baytril® Max 100mg/ml Solution for Injection for Cattle and Pigs, which replaces the company's previously animal-specific Baytril Max products.
Bayer says the active ingredient, enrofloxacin, treats bacterial infection by inhibiting the action of bacterial DNA gyrase resulting in bacterial cell death.
In cattle, Baytril Max treats respiratory infections and mastitis caused by enrofloxacin-sensitive Histophilus somni, Mannheimia haemolytica, Pasteurella multocida and Mycoplasma spp., and enrofloxacin-sensitive E. coli respectively.
In pigs, Baytril Max targets bacterial bronchopneumonia caused by enrofloxacin-sensitive Actinobacillus pleuropneumoniae, Pasteurella multocida and complicated by Haemophilus parasuis as a secondary pathogen in pigs.
Bayer advises that vets treating cattle for respiratory infections should inject subcutaneously. Mastitis cases should be treated intravenously and pigs should be injected intramuscularly in the neck muscles, behind the ear.
The development of the Baytril Max product family provides vets with greater treatment flexibility from one solution.
For further information please visit www.noahcompendium.co.uk
Merial Animal Health has been found in breach of the NOAH Code of Practice for literature promoting the wormer Ivomec Super.
In the literature, Merial stated that Closantel injection (Janssen Animal Health) was effective against flukes aged 9 weeks or older, when in fact, at the time the undated brochure was distributed, Closantel was effective against flukes aged 7 weeks or older.
Merial did not dispute the facts alleged: the company had relied on an out-of-date detailer. The NOAH Code of Practice Committee emphasised the need for members to ensure, when giving comparative data in promotions, that up-to-date data is used. The SPC of any authorised product can be viewed on the VMD's website.
The Committee did commend Merial Animal Health for taking corrective action within two days of notification by the Complainant.
NOAH encourages those interested in finding out more to read the full details of the Committee's rulings on the NOAH website at www.noah.co.uk/code.
The study, published in Nature Scientific Reports, investigated the effect of culling in the first three licensed badger cull areas – Gloucestershire, Somerset and Dorset – using data from 2013 to 2017.
Gloucestershire and Somerset saw reductions in bTB incidence rates in cull areas relative to comparison areas of 66 per cent and 37 per cent respectively after four years. In Dorset, there was no change in incidence rates in cull areas relative to comparison areas after two years, but incidence dropped by 55 per cent in the same period in the 2km buffer zone around the edge of the cull area. Matched comparison areas were similar but not identical.
James Russell, BVA Junior Vice President said: "These findings are encouraging and offer further evidence that badger culling can result in significant reductions in the number of new cases of TB in cattle. However, they come with the caveat that the data only relates to the first three cull areas, and the variability within these alone makes it too early to draw firm conclusions that culling will reduce incidence significantly in all 40 areas where it is now taking place.
"BVA’s expert working group is currently considering all aspects of disease control looking at cattle testing, removal of reactors, compensation and control in other farmed animals as well as the culling and vaccination of badgers. The group will consider this additional evidence as we develop our new policy on bTB.
"We continue to support a comprehensive and evidence-based approach to tackling bTB, including the use of badger culling where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy.
"The best way of halting the spread of this devastating disease is enhancing our understanding of bTB and applying that evidence to the eradication process.”
MSD Animal Health has launched Zuprevo Cattle, which contains a novel antibiotic molecule to help combat bovine respiratory disease (BRD).
Zuprevo Cattle contains the active ingredient tildipirosin (180mg/ml), a new 16-membered, tribasic macrolide unique to animal health. It is licensed for the treatment and prevention of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
According to MSD Animal Health livestock veterinary adviser Paul Williams MRCVS, the new product works extremely quickly in the animal, as well as offering the longest duration of activity in the lungs of all the macrolide antibiotics currently on the market. He says it is also extremely convenient to use: "Zuprevo is readily absorbed by the animal, reaching peak plasma concentrations within 23 minutes of injection. Zuprevo is readily distributed around the body and reaches lung concentration well above MIC90 for all of the three BRD target pathogens within four hours of administration. In addition, it maintains lung concentration above the MIC90 for up to 28 days, which will appeal to many practitioners."
Paul says that it is Zuprevo's 16-membered, tribasic macrolide structure that allows it to deliver these significant pharmacological benefits for the management of BRD in cattle: "Zuprevo works by diffusing into the bacterial cell where its binding action inhibits protein synthesis of the bacterial ribosome. Its unique 16-membered, tribasic structure enables enhanced penetration of the bacterial cell wall, as well as having the ability to bypass some potential bacterial resistance mechanisms."
Paul says Zuprevo also offers vets and their farmer clients important practical usage advantages: "Zuprevo is an easily syringeable solution for injection available in convenient 20ml, 50ml and 100ml vial sizes to suit different usage requirements. At a dose rate of 1ml/45kg, it offers the lowest macrolide dose volume per kg of bodyweight. At 47 days, Zuprevo also has the shortest macrolide meat withdrawal period."
Further information on this new macrolide antibiotic is available from the MSD Animal Health territory managers or by calling the company's Veterinary Services Group on 01908 685685.
Gabbrovet Multi is the first and only ready-to-use solution licensed to treat both cryptosporidium and E.coli diarrhoea in calves.
The company highlights a study of 334 calves with severe diarrhoea, where those receiving Gabbrovet Multi showed a faster and more effective response than those given halofuginone1.
Harry Walby, ruminant veterinary advisor at Ceva Animal Health, said: “Gabbrovet Multi is the first and only ready-to-use solution for the convenient treatment of both cryptosporidium and E.coli, two of the most common causes of neonatal scour in calves."
Gabbrovet Multi can be administered in milk or water.
It is available with a dosing cap and comes in 250ml, 500ml or 1l presentations.
Gabbrovet Multi also treats gastro-intestinal infections caused by E.coli in pigs.
For further information, contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
The Veterinary Record has published what the British Homeopathy Association is calling the first ever systematic review of randomised controlled trials (RCTs) in veterinary homeopathy.
The review was conducted by Dr Robert Mathie, research development adviser to the association, and Dr Jürgen Clausen from the Carstens Foundation, Germany.
They found 18 placebo-controlled RCTs of veterinary homeopathy, published in the peer-reviewed literature, that were eligible for detailed assessment. Of these, only two were judged to provide reliable evidence. The remainder were unclear or had a high risk of bias.
The two studies which were judged reliable were:
HEKTOEN, L., LARSEN, S., ØDEGAARD, S. A. & LOKEN, T. (2004) Comparison of homeopathy, placebo and antibiotic treatment of clinical mastitis in dairy cows - methodological issues and results from a randomized-clinical trial. Journal of Veterinary Medicine. A, Physiology, pathology, clinical medicine 51, 439-446. In this study, homeopathy was shown to be ineffective.
Dr Mathie said: "Up to now, debates about the efficacy or effectiveness of veterinary homeopathy have been polarised by the absence of any systematic review of the subject. Our work clarifies the nature of the current RCT evidence."
Mr Mark Elliott, immediate past president of the British Association of Homeopathic Veterinary Surgeons, said: "This important study affirms that reliable evidence does exist and that more research should be done, particularly in light of current concerns about antibiotic resistance in production animals."
It seems a remarkable admission, that the entire veterinary homeopathy edifice rests upon one study in piglets. However, if that study did prove the efficacy of homeopathy, it would of course be an order of magnitude more remarkable than today's admission.
So, no pressure then, Camerlink et al!
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.